TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sentinel Lymph Node identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: CR/CRh rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post ERCP Acute Pancreatitis (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of participants reporting solicited local or systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting adverse events leading to discontinuation from study vaccine/study withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment persistence rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Continuous Glucose Monitor (CGM) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in general pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in emergency contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve (AUC) of the MRD biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goniometer for cervical range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of Mesobotox in treating plaque psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Mesobotox in treating plaque psoriasis
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Transepidermal Water Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Study Adherence (daily app survey)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study Adherence (weekly symptom survey)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study Adherence (Wearable device)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in renal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dysplasia detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of activation through EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant laboratory examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best spectacle-corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Concentration Specific for GBS-NN and GBS-NN2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Responses Specific to AlpCN, RibN, Alp1N and Alp2-3N
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in acute insulin response to arginine (AIRarg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in acute C-peptide (ACRarg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WURSS-21 Total QoL Domains Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Numerical Rating Scale Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety Sensitivity Index-3 (ASI-3) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Global Impressions/Severity Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Functional changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health-Related Quality-of-Life changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inorganic phosphate (PPi) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement of cellular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue fat tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Senescent cell-cycle arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose control (insulin resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO Quality of Life assessment (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of downstaging of peritoneal disease burden to become resectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and severity of dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal voluntary breath-hold time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in infarct-core volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreas volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pancreas T1 signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pancreas secreted fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC0-inf,etavopivat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,etavopivat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½,etavopivat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis improvement in patients with psoriasis Vulgaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Hall Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate after five days of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of segments of the left ventricle with regional wall motion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum treatment interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Endometriosis Health Profile Questionnaire (EHP-30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Agreement between plasma glucose and CGM measured glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody Concentrations Against SARS-CoV-2 Spike Protein-specific IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Client Satisfaction Scale - Parent (CSQ-8-P)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client Satisfaction Scale - Child (CSQ-8-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Acceptability Questionnaire - Parent (PAQ-P)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Acceptability Questionnaire - Child (PAQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects with no progression
Endpoint domain: Mortality/survival
Primary endpoint: frequency of bronchiectasis exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of allograft liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of Walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy- clinical recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in offset analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in brain region activation- QST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in brain region activation- walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in brain region activation- stair climbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Central Corneal Endothelial Cell Density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum dilatation size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Vaccine efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 Vaccine safety
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Improvement of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of lumbar aortic lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Percentage of fat mass and total and regional lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricle (LV) systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with HBsAg loss at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with HBsAg loss at 24 weeks post-end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of complex permittivity of breast tissue components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT-B questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glycemic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Experience a Dose Interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience a Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants exclusively breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall duration of any breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Per-implant bone density measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed Pain Intensity Difference From 0-24 Hours (SPID0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing promoting effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Peak Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the plasma nicotine concentration-time Curve (AUC) at 120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tragus to wall distance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intensity of surgical pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue doses of analgesics administered after operation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Shift of patients to ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of the Clinician Report to clinicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability and utility of the ePROM Patient Survey and Clinician Report to patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of Vulvar Lichen Sclerosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of symptom distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EDS (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Conjunctival Sum Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (ORR) per RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean percent change in LDL-C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean absolute change in LDL-C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving the guideline-recommended LDL-C target at any time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Rankin Scale (mRS) Score at Day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EASI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of the disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Saturation by pulse oximetry (Sp02)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of central nervous system infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in the masticatory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in the BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genomic markers of progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-TPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Grade 3+ GU/GI toxicity-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Neurogenic bladder symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of Social Inference
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social Attribution
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotion Identification
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of testing positive for SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Change in expression of markers of autophagy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of CCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of bi-4SCAR-CD19/79b T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Wound healing assessment on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing assessment on day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Sleep Latency (MSL)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Diffusing Capacity of the Lungs for Carbon Monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: White Matter Hyperintensity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-op bone quality evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal sepsis risk
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Target Limb Salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major device-related bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Device-related Serious adverse effects (SAE) and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Total sugar purchased
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total saturated fat purchased
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total sodium purchased
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in maxillary width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGA-AHE score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cyclic Mean Curvature of Pacing and Defibrillation Leads in the Extravenous Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cyclic Mean Curvature of Pacing and Defibrillation Leads in the Intracardiac Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cyclic Mean Curvature of Pacing and Defibrillation Leads in the Connector Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of pruritus (itching)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of referrals at 6-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mid-upper arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Proportion of mothers exclusive breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ED-15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in 4 'A's Test (4AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Intensive Care Delirium Screening Checklist (ICDSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy on elicited production probes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of belatacept in kidney transplant recipients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in heparan sulfate concentrations in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurocognitive testing (BSID-III or KABC-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurocognitive testing (VABS-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurocognitive testing (Wechsler)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of pulp inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of dentin chips formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathy as measured by the Jefferson Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Assessment of Clinical Reflection and Reasoning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent lactulose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in length-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Selection of the appropriate supraglottic airway device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Brain Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent change in bone formation marker, P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change in Visual Analog Scale (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal exposure to inhalable protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes